// Company Overview //
Stock Name Jitai Technology
Stock Code 07666
Company Full Name Jitai Technology
Industry 生物医药
Principal Activities 我们是人工智能纳米材料创新的领军者,致力于有效载荷在各种生命体中的递送与应用,以AI纳米创新开启健康未来。
Listing Date 2026-05-13
Listing Rules Era New Rules (after Aug 2025)
Listing Rules Chapter 18C特专科技
Weighted Voting Rights (WVR) No
Registered Address (Mainland China) 中國北京市大興區中關村科技園大興生物醫藥產業基地天河西路21號13號樓2層201室
Business Address (Hong Kong) 香港銅鑼灣希慎道33號利苑一期19樓1920室
Place of Incorporation No data
Listing Method No data
Listing Board Main Board
Website www.metistechbio.com
Share Registrar 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact (852)2862 8628
A-Share/US Dual Listing No
// Offering Information //
Offering Mechanism
18C特专科技
Clawback Tiers 因超购6,911.0倍,回拨至20.0%
Offer Period 2026-05-05 to 2026-05-08
Offer Price HK$ 10.50 / shares
Offer Price Range Final offer price only, no range
Lot Size 500 shares
Entry Threshold HK$ 5,250
Par Value RMB 0.1 / shares
Global Offering Shares 201,229,000
HK Public Offering Shares 40,246,000 (20.0%)
International Placing Shares — (0.0%)
Offer Ratio ~17.46%
Total Shares Post-IPO 1,152,513,850 shares
Total Global Offering Size HK$ 2,112,904,500
Public Offering Size HK$ 422,583,000 (20.0%)
Oversubscription Multiple 6,911.0x
Valid Applications 383,309
Accepted Applications 65,740
Reallocation No
Total Funds Raised HK$ 422,583,000
Greenshoe (Over-allotment Option) No
Final Public Offering Share 20.0%
// Valuation & Financials //
Market Cap (at Offer Price) HK$ 12,101,395,425
Pre-IPO Valuation (Last Round) No data
P/E Ratio 不适用(公司处于亏损状态)
Profit/Loss Status 亏损人民币391.8百万元
Period-End Cash Balance 人民币561,500,000元
Listing Expenses ~HK$ 136,000,000
Listing Expenses / Funds Raised ~6.4%
Total Pre-IPO Investment No data
// First Day Performance
First Day Close Loading...
First Day Open HK$ 28.68
First Day Change 126.67%
First Day Volume 84545200.0
First Day Turnover 2403900000.0
// Price Chart //
// Use of Proceeds
Use of Proceeds 1、約988.5百萬港元(約50.0%)將用于支撐公司的人工智能基礎設施及人工智能驅動納米材料平臺的核心技術研究、開發及推進;
2、約395.4百萬港元(約20.0%)將用于公司人工智能開發產品管線中正在進行及計劃開展的臨床試驗;
3、約197.7百萬港元(約10.0%)將用于開發公司的動物健康及抗衰解決方案,并將人工智能賦能的解決方案拓展至該等高增長領域;
4、約197.7百萬港元(約10.0%)將分配用于支持公司在全球構建人工智能驅動納米材料生態系統的增長戰略;
5、約197.7百萬港元(約10.0%)將用作營運資金及其他一般企業用途。
// Underwriting Syndicate //
联席保荐人 (3)
富瑞金融集团香港有限公司
德意志证券亚洲有限公司
中信证券(香港)有限公司
保荐人兼整体协调人 (3)
富瑞金融集团香港有限公司
德意志银行香港分行
中信里昂证券有限公司
整体协调人 (4)
富瑞金融集团香港有限公司
德意志银行香港分行
中信里昂证券有限公司
招银国际融资有限公司
联席全球协调人 (4)
富瑞金融集团香港有限公司
德意志银行香港分行
中信里昂证券有限公司
招银国际融资有限公司
联席账簿管理人 (5)
富瑞金融集团香港有限公司
德意志银行香港分行
中信里昂证券有限公司
招银国际融资有限公司
富途证券国际(香港)有限公司
联席牵头经办人 (5)
富瑞金融集团香港有限公司
德意志银行香港分行
中信里昂证券有限公司
招银国际融资有限公司
富途证券国际(香港)有限公司
资本市场中介人 (5)
富瑞金融集团香港有限公司
德意志银行香港分行
中信里昂证券有限公司
招银国际融资有限公司
富途证券国际(香港)有限公司
// Service Providers //
Role Institution
本公司法律顾问
达维律师事务所
汉坤律师事务所
保荐人/包销商法律顾问
美迈斯律师事务所
通商律师事务所
核数师兼申报会计师
罗兵咸永道会计师事务所
行业顾问
弗若斯特沙利文有限公司
合规顾问
浤博资本有限公司
收款银行
招商永隆银行有限公司
H股证券登记处
香港中央证券登记有限公司
// Cornerstone Investors //
Allotment Results Announcement
# Investor Name Shares Subscribed % of Offer Shares % of Total Shares Lock-up Period Est. Unlock Date
1
貝萊德
37,304,500
3.24%
—
2026-11-12
2026-11-12
2
UBSAMSingapore
11,191,000
0.97%
—
2026-11-12
2026-11-12
3
國風投創新投資基金股
7,460,500
3.71%
0.71%
2026-11-12
2026-11-12
4
未來資產
5,968,500
2.97%
0.57%
2026-11-12
2026-11-12
5
HHLRA
5,968,500
0.52%
—
2026-11-12
2026-11-12
6
Yael Capital
4,477,000
2.22%
0.43%
—
—
7
Martis Fund
3,730,500
1.85%
0.35%
—
—
8
RTW基金
3,730,000
1.85%
0.35%
2026-11-12
2026-11-12
9
廣發基金
3,730,000
1.85%
0.35%
2026-11-12
2026-11-12
10
華夏基金(香港)
3,730,000
1.85%
0.35%
2026-11-12
2026-11-12
11
富國基金
3,730,000
1.85%
0.35%
2026-11-12
2026-11-12
12
Deerfield
3,730,000
0.32%
—
2026-11-12
2026-11-12
13
ArcAvenue
3,730,000
0.32%
—
2026-11-12
2026-11-12
14
HuadengTechnology
3,730,000
0.32%
—
2026-11-12
2026-11-12
15
IsometryGlobal
3,730,000
0.32%
—
2026-11-12
2026-11-12
16
工銀瑞信實體
3,730,000
0.32%
—
2026-11-12
2026-11-12
17
LakeBleu
2,984,000
0.26%
—
2026-11-12
2026-11-12
18
SagePartners
2,984,000
0.26%
—
2026-11-12
2026-11-12
19
中信證券國際資本管理
2,348,500
1.17%
0.22%
—
—
20
工銀理財
1,492,000
0.13%
—
2026-11-12
2026-11-12
21
ORIXAsiaAM
1,492,000
0.13%
—
2026-11-12
2026-11-12
22
滙豐環球投資管理(香
373,000
0.19%
0.04%
—
—
23
中國人壽富蘭克林資產
261,000
0.13%
0.02%
—
—
24
嘉實國際資產管理有限
12,000
0.01%
0.00%
—
—
25
德意志投資香港有限公
12,000
0.01%
0.00%
—
—
26
中信証券資產管理有
1,500
0.00%
0.00%
—
—
27
中信證券資產管理(香
1,500
0.00%
0.00%
—
—
// Directors & Management //
Chairman 赖才达
Company Secretary 付翀
執行董事 (3)
# Name English Name Type
1
赖才达
—
執行董事
2
Hongming Chen
—
執行董事
3
王文首
—
執行董事
非執行董事 (2)
# Name English Name Type
1
黄瀚涛
—
非執行董事
2
公元
—
非執行董事
獨立非執行董事 (2)
# Name English Name Type
1
林怡仲
—
獨立非執行董事
2
李晋
—
獨立非執行董事
// Major Shareholders //
Major Shareholders & Holdings 紧随全球发售完成后,单一最大股东集团(包括一致行动人士赖博士、Chen博士、王博士及Scientia HK,以及雇员激励平台南京承泰裕鑫、Delos Holding、杭州盛泰及Dechi Holding)将直接或间接合共持有本公司总股本约25.32%。
// Allotment Benchmarks //
Expand Allotment Tiers ▼ ▾
Pool A (Small Subscriptions)
Shares Applied Applicants Allottees Expected Lots
500
93,334
132
0.00
1,000
18,254
52
0.00
1,500
10,141
43
0.00
2,000
19,104
108
0.01
2,500
9,301
66
0.01
3,000
7,928
67
0.01
3,500
3,341
33
0.01
4,000
4,849
55
0.01
4,500
7,406
94
0.01
5,000
11,684
165
0.01
6,000
4,628
79
0.02
7,000
4,081
81
0.02
8,000
8,387
190
0.02
9,000
8,546
218
0.03
10,000
14,292
405
0.03
15,000
10,263
436
0.04
20,000
8,514
482
0.06
25,000
6,592
466
0.07
30,000
5,475
465
0.08
35,000
3,934
390
0.10
40,000
3,937
446
0.11
45,000
3,223
411
0.13
50,000
7,194
1,018
0.14
60,000
4,694
797
0.17
70,000
3,578
709
0.20
80,000
4,111
931
0.22
90,000
3,663
933
0.25
100,000
18,906
5,351
0.28
200,000
12,147
6,876
0.56
300,000
8,069
6,852
0.84
400,000
10,507
1,388
1.12
Pool B (Large Subscriptions)
Shares Applied Applicants Allottees Expected Lots
500,000
22,231
8,087
0.40
1,000,000
8,076
5,876
0.80
1,500,000
3,977
363
1.20
2,000,000
2,363
1,075
1.60
2,500,000
1,455
1,192
2.00
3,000,000
989
181
2.40
3,500,000
650
355
2.80
4,000,000
949
864
3.20
5,030,500
2,536
1,674
4.02
Disclaimer & Risk Warning Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.
Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.
Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.
Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.
Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.